RT Journal Article
T1 CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.
A1 Frantzi, Maria
A1 Gomez Gomez, Enrique
A1 Blanca Pedregosa, Ana
A1 Valero Rosa, Jose
A1 Latosinska, Agnieszka
A1 Culig, Zoran
A1 Merseburger, Axel S
A1 Luque, Raul M
A1 Requena Tapia, Maria Jose
A1 Mischak, Harald
A1 Carrasco Valiente, Julia
K1 Algorithms
K1 Biomarkers, tumor
K1 Case-control studies
K1 Electrophoresis, capillary
AB Prostate cancer progresses slowly when present in low risk forms but can be lethal when it progresses to metastatic disease. A non-invasive test that can detect significant prostate cancer is needed to guide patient management. Capillary electrophoresis/mass spectrometry has been employed to identify urinary peptides that may accurately detect significant prostate cancer. Urine samples from 823 patients with PSA ( Independent validation of the 19-biomarker model in 280 patients resulted in a 90% sensitivity and 59% specificity, with an AUC of 0.81, outperforming PSA (AUC = 0.58) and the ERSPC-3/4 risk calculator (AUC = 0.69) in the validation set. This multi-parametric model holds promise to improve the current diagnosis of significant prostate cancer. This test as a guide to biopsy could help to decrease the number of biopsies and guide intervention. Nevertheless, further prospective validation in an external clinical cohort is required to assess the exact performance characteristics.
PB Nature Publishing Group
YR 2019
FD 2019-04-16
LK http://hdl.handle.net/10668/13969
UL http://hdl.handle.net/10668/13969
LA en
DS RISalud
RD Apr 18, 2025